Organogenesis Holdings Inc. (NASDAQ:ORGO) Short Interest Down 18.2% in November

Organogenesis Holdings Inc. (NASDAQ:ORGO) was the recipient of a large decline in short interest in November. As of November 30th, there was short interest totalling 8,520,000 shares, a decline of 18.2% from the November 15th total of 10,410,000 shares. Based on an average daily volume of 655,500 shares, the days-to-cover ratio is currently 13.0 days. Approximately 11.9% of the shares of the company are short sold.

Insider Activity

In related news, CEO Gary S. Gillheeney sold 18,416 shares of the business’s stock in a transaction on Friday, December 6th. The shares were sold at an average price of $3.65, for a total value of $67,218.40. Following the completion of the sale, the chief executive officer now owns 3,400,778 shares of the company’s stock, valued at approximately $12,412,839.70. The trade was a 0.54 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold a total of 216,916 shares of company stock valued at $784,832 in the last three months. 36.90% of the stock is currently owned by corporate insiders.

Institutional Trading of Organogenesis

Several large investors have recently added to or reduced their stakes in the stock. Captrust Financial Advisors purchased a new stake in shares of Organogenesis in the third quarter valued at about $36,000. Pallas Capital Advisors LLC purchased a new stake in shares of Organogenesis in the 2nd quarter valued at approximately $38,000. Delap Wealth Advisory LLC acquired a new stake in shares of Organogenesis during the 2nd quarter worth approximately $40,000. Intech Investment Management LLC purchased a new stake in shares of Organogenesis during the 3rd quarter valued at approximately $43,000. Finally, Allspring Global Investments Holdings LLC lifted its holdings in Organogenesis by 4,989.9% in the second quarter. Allspring Global Investments Holdings LLC now owns 15,677 shares of the company’s stock valued at $44,000 after acquiring an additional 15,369 shares during the last quarter. 49.57% of the stock is currently owned by hedge funds and other institutional investors.

Organogenesis Price Performance

Organogenesis stock traded up $0.12 during midday trading on Monday, reaching $3.52. The company had a trading volume of 155,141 shares, compared to its average volume of 840,150. Organogenesis has a 12-month low of $2.16 and a 12-month high of $4.70. The firm’s fifty day simple moving average is $3.43 and its 200-day simple moving average is $3.00. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.09 and a quick ratio of 2.74. The company has a market capitalization of $466.68 million, a P/E ratio of -56.67 and a beta of 1.73.

Organogenesis (NASDAQ:ORGO) last issued its quarterly earnings results on Tuesday, November 12th. The company reported $0.09 EPS for the quarter, topping the consensus estimate of ($0.02) by $0.11. Organogenesis had a negative return on equity of 2.69% and a negative net margin of 1.62%. The firm had revenue of $115.18 million during the quarter, compared to analysts’ expectations of $109.59 million. During the same period in the previous year, the business earned $0.02 earnings per share. As a group, equities analysts anticipate that Organogenesis will post -0.07 EPS for the current year.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.